Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Stripe, Advent in Talks to Buy PayPal (WSJ EN) +++ PAYPAL Aktie +3,08%

EISAI Aktie

 >EISAI Aktienkurs 
26.31 EUR    -1.8%    (TradegateBSX)
Ask: 26.18 EUR / 189 Stück
Bid: 25.66 EUR / 192 Stück
Tagesumsatz: 515 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
EISAI Aktie über LYNX handeln
>EISAI Performance
1 Woche: +3,6%
1 Monat: +17,2%
3 Monate: +4,3%
6 Monate: -4,4%
1 Jahr: +2,8%
laufendes Jahr: +5,1%
>EISAI Aktie
Name:  EISAI CO. LTD
Land:  Japan
Sektor:  Gesundheit
ISIN/ Wkn:  JP3160400002 / 855526
Symbol/ Ticker:  EII (Frankfurt)
Kürzel:  FRA:EII, ETR:EII, EII:GR
Index:  Nikkei225
Webseite:  https://www.eisai.com/
Profil:  Eisai Co., Ltd. is a major pharmaceutical company specializing in the research, development, and manufacture of innovative pharmaceuticals. Its primary function is to deliver prescription drugs and therapies aimed at treating neurological disorders, ..
>Volltext..
Marktkapitalisierung:  7643.92 Mio. EUR
Unternehmenswert:  7569.72 Mio. EUR
Umsatz:  4570.29 Mio. EUR
EBITDA:  443.06 Mio. EUR
Nettogewinn:  225.7 Mio. EUR
Gewinn je Aktie:  0.8 EUR
Schulden:  1446.94 Mio. EUR
Liquide Mittel:  1662.36 Mio. EUR
Operativer Cashflow:  307.37 Mio. EUR
Bargeldquote:  0.79
Umsatzwachstum:  -2.45%
Gewinnwachstum:  -23.13%
Dividende je Aktie:  0.89 EUR
Dividendenrendite:  3.21%
Dividendenschätzung:  3.17%
Div. Historie:  30.03.26 - 0.43682963€
29.09.25 - 0.455808€
>weitere anzeigen...
Insiderhandel:  -
Suchwörter:  EISAI
Letzte Datenerhebung:  14.08.26
>EISAI Kennzahlen
Aktien/ Unternehmen:
Aktien: 282.46 Mio. St.
Frei handelbar: 90%
Leerverk. Aktien: -
Rückkaufquote: -
Mitarbeiter: 10543
Umsatz/Mitarb.: 0.43 Mio. EUR
Analysten:
Analystenrating: Neutral
Kursziel: -7.89%
Bewertung:
KGV: 32.6
KGV lG: 24.23
KUV: 1.68
KBV: 1.52
PEG-Ratio: -
EV/EBITDA: 17.08
Rentabilität:
Bruttomarge: 76.7%
Gewinnmarge: 4.94%
Operative Marge: 5.11%
Managementeffizenz:
Gesamtkaprendite: 2.85%
Eigenkaprendite: 4.88%
>EISAI Peer Group
Gesundheit, Demenz/ Alzheimer- Behandlung, Neurologische Erkrankungen/ Schlaganfälle, Onkologie/ Krebs- Behandlung
 
06.08.26 - 18:24
 Nuvation Bio outlines $30M Eisai milestone timing while expanding safusidenib studies with PFS readouts expected in 2029 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.08.26 - 11:18
 Earnings Call: Eisai übertrifft Umsatzprognose in Q1 2026, Aktie gibt dennoch um 3,6 % nach (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
03.08.26 - 11:18
 Eisai übertrifft Umsatzprognose in Q1 2026, Aktie gibt dennoch um 3,6 % nach (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
03.08.26 - 09:27
 Eisai GAAP EPS of ¥64.71, revenue of ¥234.3B; updates FY 2026 outlook (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
03.08.26 - 09:24
 Eisai Q1 Net Income Rises (AFX)
 
BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - Eisai Co. (4523.T, EII.SG) reported that its first-quarter profit attributable to owners of the parent increased 26.0% to 18.24 billion yen from 14.47 billion ......
29.07.26 - 12:39
 Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026 (PR Newswire)
 
STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 29.3......
29.07.26 - 12:33
 Sales of Leqembi® totaled 29.3 billion yen in the second quarter 2026 (PR Newswire)
 
STOCKHOLM, July 29, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi for the second quarter 2026, in conjunction with their partner Biogen's second quarter report. In total, sales of JPY 29.3......
29.07.26 - 10:48
 Eisai and CORE Biomedicine agree on global licence for oncology pipeline (PBR)
 
The deal grants CORE Biomedicine rights to develop and commercialise a portfolio of cancer therapies originally discovered by Eisai and its affiliates. The licensed assets focus on targeting The post Eisai and CORE Biomedicine agree on global licence for oncology pipeline appeared first on Pharmaceutical Business review....
28.07.26 - 14:27
 CORE Biomedicine Signs Exclusive Licensing Agreement with Eisai for Precision Oncology Programs (PR Newswire)
 
BOSTON and TOKYO, July 28, 2026 /PRNewswire/ -- CORE Biomedicine, an innovative drug discovery company developing next-generation precision medicines for broader populations of cancer patients, announced a licensing agreement with Eisai Co., Ltd., granting CORE exclusive global rights to......
14.07.26 - 19:54
 Eisai, Biogen Report Study Showing Long-Term Benefits Of LEQEMBI In Early Alzheimer′s Disease (AFX)
 
WESTON (dpa-AFX) - Eisai Co Ltd (ESALY.PK) and Biogen Inc. (BIIB) announced on Tuesday new real-world data showing that 82.5 percent of patients with early Alzheimer's disease remained stable or i......
14.07.26 - 17:45
 More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 (PR Newswire)
 
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients with early Alzheimer's disease (AD) enrolled in the......
14.07.26 - 17:42
 More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 (PR Newswire)
 
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented results from the real-world Lecanemab in Early Alzheimer's Disease (LEADER) Study showing that nearly 83% of patients with early Alzheimer's disease (AD) enrolled in the......
14.07.26 - 04:45
 FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer′s disease (PR Newswire)
 
STOCKHOLM, July 14, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection......
14.07.26 - 04:42
 FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer′s disease (PR Newswire)
 
STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection......
13.07.26 - 10:03
 Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer′s Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer′s Association International Conference® (AAIC®) 2026 (PR Newswire)
 
Measuring the plasma eMTBR-tau243 biomarker may serve as a practical, less invasive method of capturing Alzheimer's disease-specific pathological changes and may play an important role in etalanetug's future clinical development TOKYO, July 13, 2026 /PRNewswire/ -- Eisai Co., Ltd. today......
13.07.26 - 06:12
 New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer′s disease (PR Newswire)
 
STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous......
13.07.26 - 06:06
 New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer′s disease (PR Newswire)
 
STOCKHOLM, July 13, 2026 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous......
12.07.26 - 17:30
 New clinical data on the Leqembi® subcutaneous autoinjector presented at AAIC® 2026 support similar efficacy and safety to IV formulation in early Alzheimer′s disease (Cision)
 
Stockholm, Sweden, July 12, 2026 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today presented new data at the 2026 Alzheimer's Association International Conference (AAIC), held in London, July 12-15, demonstrating that the Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) formulation offers efficacy and safety comparable to intravenous (IV) administration in people with early Alzheimer's disease. The findings support a fully subcutaneous treatment pathway from initiation through maintenance treatment, offering greater convenience and flexibility for patients and care...
30.06.26 - 08:57
 New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026 (PR Newswire)
 
STOCKHOLM, June 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) in London, July 12-15, including data on its......
30.06.26 - 08:48
 New clinical and real-world evidence on Lecanemab to be presented at AAIC conference 2026 (PR Newswire)
 
STOCKHOLM, June 30, 2026 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ STOCKHOLM: BIOA B) partner Eisai will present new clinical and real-world evidence on lecanemab (Leqembi®) at the Alzheimer's Association International Conference (AAIC) in London, July 12-15, including data on its......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Ein Hafen ist ein reizvoller Aufenthalt für eine im Lebenskampf erschöpfte Seele. - Charles Baudelaire
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!